Compare Nucor Corporation (NUE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Twist Bioscience Corp — how do they compare? Nucor Corporation trades at $230.8 (market cap $52.55B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Nucor Corporation is far larger — about 9.6× Twist Bioscience Corp's market cap, and Nucor Corporation pays a 0.97% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NUE | TWST | |
|---|---|---|
Market Cap | $52.55B | $5.45B |
Sector | Basic Materials | Health |
52-Week High | $266.35 | $102.88 |
52-Week Low | $131.78 | $24.16 |
Enterprise Value | $57.19B | $5.37B |
Dividend Yield | 0.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $233.2, down 1.44% over 24 hours, with technical indicators showing a bearish trend near key support at $228. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has stabilized around $32.5B in 2025 after declines from 2022 peaks, while net margins compressed to 5.36%. Analyst sentiment remains positive with a 62.5% buy rating and $263.11 consensus target, supported by strong cash flow and a 53-year dividend growth streak.
NUE offers value with reasonable valuation multiples (P/E 22.89, P/S 1.55) and robust shareholder returns, but faces risks from steel demand volatility and margin pressure. The upcoming Q2 earnings report on July 27, 2026, will be critical for confirming growth trajectory amid economic uncertainties.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
